{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:59:57Z","timestamp":1789664397547,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.semarthrit.2008.04.004","type":"journal-article","created":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T05:32:24Z","timestamp":1214890344000},"page":"116-122","source":"Crossref","is-referenced-by-count":51,"title":["Effect of Tumor Necrosis Factor Alpha Inhibition on Bone Density and Turnover Markers in Patients with Rheumatoid Arthritis and Spondyloarthropathy"],"prefix":"10.1016","volume":"39","author":[{"given":"Cheryl","family":"Barnabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2008.04.004_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.rdc.2006.07.002","article-title":"Epidemiology of osteoporosis in rheumatic diseases","volume":"32","author":"Sinigaglia","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.rdc.2006.07.004","article-title":"Inflammation-induced bone loss: can it be prevented?","volume":"32","author":"Romas","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002281-199607000-00015","article-title":"Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone","volume":"8","author":"Henderson","year":"1996","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMcp043801","article-title":"Postmenopausal osteoporosis","volume":"353","author":"Rosen","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib5","first-page":"370","article-title":"An update on glucocorticoid-induced osteoporosis","volume":"19","author":"Woolf","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib6","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2008.04.004_bib7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/BOR.0b013e328172dc1a","article-title":"New and emerging treatments for osteoporosis","volume":"19","author":"Maricic","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib8","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib9","first-page":"1356","article-title":"Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-\u03b1 directed therapies in the treatment of spondyloarthritis","volume":"30","author":"Maksymowych","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2007.076604","article-title":"Long term effects of Infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","author":"Chopin","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2008.04.004_bib11","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar2219","article-title":"A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab","volume":"9","author":"Marotte","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1196\/annals.1351.040","article-title":"Bone metabolism changes during anti-TNF-\u03b1 therapy in patients with active rheumatoid arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF\u03baB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","article-title":"Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-\u03b1 antibody: a prospective open-label pilot study","volume":"44","author":"Lange","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/ard.2004.028670","article-title":"Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor \u03b1 treatment","volume":"64","author":"Briot","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ard.62.4.347","article-title":"Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor \u03b1","volume":"62","author":"Allali","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 28","key":"10.1016\/j.semarthrit.2008.04.004_bib17","first-page":"S185","article-title":"Infliximab in spondyloarthropathy\u2014influence on bone density","volume":"20","author":"Demis","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2007.076711","article-title":"Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis","author":"Gengenbacher","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2008.04.004_bib19","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/art.11292","article-title":"Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab","volume":"48","author":"Vis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib20","first-page":"473","article-title":"Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab","volume":"21","author":"Hermann","year":"2003","journal-title":"Clin Exp Rheum"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kei280","article-title":"The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis","volume":"45","author":"Torikai","year":"2006","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.semarthrit.2008.04.004_bib22","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","article-title":"High levels of osteoprotegerin and soluble receptor activator of nuclear factor \u03baB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor \u03b1 treatment","volume":"46","author":"Ziolkowska","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2008.04.004_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/BOR.0b013e328133f57b","article-title":"Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis","volume":"19","author":"Toussirot","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2008.04.004_bib24","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bone.2004.07.004","article-title":"TNF-\u03b1 antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis","volume":"35","author":"Saidenberg-Kermanac'h","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib25","first-page":"1465","article-title":"Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2008.04.004_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.20870","article-title":"Cartilage biomarkers in ankylosing spondylitis","volume":"52","author":"Kim","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2008.04.004_bib27","first-page":"673","article-title":"[Change in biomarkers of osteoporosis in rheumatoid arthritis patients treated with infliximab]","volume":"111","author":"Korczowska","year":"2004","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.semarthrit.2008.04.004_bib28","first-page":"214","article-title":"The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab","volume":"23","author":"Ostanek","year":"2003","journal-title":"Clin Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901720800084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901720800084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T08:55:06Z","timestamp":1545900906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901720800084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S004901720800084X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2008.04.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}